EPS8L2

Across TCGA pan-cancer cohorts, EPS8L2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EPS8L2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EPS8L2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EPS8L2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where EPS8L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.430	0.893	<.001	59	view →
CCRCC	DFS	Median	II,III,IV	0.887	0.283	.012	27	view →
GBM	OS	Tertile	All	0.270	0.518	.009	6	view →
LUAD	OS	Quartile	All	1.000	0.943	.038	3	view →
HNSC	OS	Median	IV	0.833	0.645	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EPS8L2–PDAC (DFS)

Open the PDAC breakdown →